| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $29,286 | 2 | 100 |
| Rona Jeffrey A | CBFO | 0 | $0 | 1 | $12,384 | $-12,384 |
| ALEXANDER MARGARET A. | President and CEO | 0 | $0 | 1 | $16,901 | $-16,901 |
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Over the last 12 months, insiders at Ovid Therapeutics Inc. have bought $0 and sold $29,286 worth of Ovid Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Ovid Therapeutics Inc. have bought $55,336 and sold $53,543 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,810 shares for transaction amount of $4,971 was made by ALEXANDER MARGARET A. (President and COO) on 2025‑01‑27.
| 2026-02-23 | Sale | Rona Jeffrey A | CBFO | 8,541 0.012% | $1.45 | $12,384 | +18.96% | |
| 2026-02-23 | Sale | ALEXANDER MARGARET A. | President and CEO | 11,656 0.0164% | $1.45 | $16,901 | +18.96% | |
| 2025-02-26 | Sale | ALEXANDER MARGARET A. | President and COO | 5,279 0.0079% | $0.56 | $2,956 | +115.73% | |
| 2025-02-26 | Sale | Rona Jeffrey A | CBFO | 3,902 0.0058% | $0.56 | $2,185 | +115.73% | |
| 2025-01-27 | ALEXANDER MARGARET A. | President and COO | 6,810 0.0096% | $0.73 | $4,971 | -9.40% | ||
| 2024-03-18 | LEVIN JEREMY M | CEO | 18,248 0.0261% | $2.76 | $50,364 | -59.52% | ||
| 2021-07-14 | Sale | Rakhit Amit | President and CMO | 34,017 0.0508% | $3.71 | $126,203 | -10.93% | |
| 2020-08-28 | LEVIN JEREMY M | CEO | 8,488 0.0143% | $5.84 | $49,570 | -33.90% | ||
| 2019-10-08 | TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 2M 4.1699% | $2.50 | $5M | +65.16% | ||
| 2019-10-08 | LEVIN JEREMY M | CEO | 60,000 0.1251% | $2.50 | $150,000 | +65.16% | ||
| 2019-02-26 | Bernstein Karen | director | 10,000 0.0325% | $2.02 | $20,210 | +7.32% | ||
| 2019-02-22 | LEVIN JEREMY M | CEO | 75,000 0.2617% | $2.00 | $150,000 | +15.34% | ||
| 2018-08-14 | Bernstein Karen | director | 20,000 0.0386% | $3.12 | $62,300 | -60.76% | ||
| 2018-08-14 | WILLIAMS DOUGLAS E | director | 10,000 0.0201% | $3.24 | $32,442 | -60.76% | ||
| 2017-08-25 | LEVIN JEREMY M | CEO | 30,668 0.062% | $3.58 | $109,638 | +20.31% |
| Rona Jeffrey A | CBFO | 88188 0.1238% | $171,966.60 | 0 | 2 | |
| ALEXANDER MARGARET A. | President and CEO | 61750 0.0867% | $120,412.50 | 1 | 2 | |
| TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 5750000 8.0744% | $11.21M | 1 | 0 | +65.16% |
| LEVIN JEREMY M | CEO | 3616715 5.0788% | $7.05M | 5 | 0 | +33.6% |
| Rakhit Amit | President and CMO | 726823 1.0206% | $1.42M | 0 | 1 | |
| Bernstein Karen | director | 20000 0.0281% | $39,000.00 | 2 | 0 | <0.0001% |
| WILLIAMS DOUGLAS E | director | 5000 0.007% | $9,750.00 | 1 | 0 | <0.0001% |
$9,405,928 | 107 | 12.61% | $119.21M | |
$8,291,525 | 53 | 3.09% | $135.49M | |
$66,137,559 | 49 | 6.29% | $133M | |
$18,994,888 | 46 | 88.59% | $129.89M | |
$48,218,096 | 42 | 0.89% | $134.03M | |
$7,147,964 | 34 | 24.77% | $139.47M | |
$109,415,500 | 33 | 18.13% | $141.7M | |
$38,601,028 | 29 | 1.18% | $128.52M | |
$47,292,212 | 27 | -28.21% | $159.96M | |
$295,092,700 | 21 | -0.27% | $134.87M | |
$111,692,551 | 18 | 13.51% | $142.8M | |
$178,593,887 | 15 | -14.86% | $124.78M | |
$9,999,920 | 10 | -40.03% | $118.66M | |
$13,919,584 | 9 | -30.43% | $143.94M | |
$2,762,881 | 8 | -10.76% | $140.59M | |
$22,090,972 | 7 | -3.49% | $145.92M | |
Ovid Therapeutics Inc. (OVID) | $5,524,590 | 7 | 7.40% | $138.86M |
$164,999,952 | 5 | -44.44% | $151.69M | |
$63,731 | 1 | -19.50% | $159.35M |
| Increased Positions | 47 | +50% | 42M | +145.55% |
| Decreased Positions | 39 | -41.49% | 8M | -29.24% |
| New Positions | 21 | New | 28M | New |
| Sold Out Positions | 13 | Sold Out | 3M | Sold Out |
| Total Postitions | 102 | +8.51% | 62M | +116.31% |
| Vanguard Group Inc | $4,965.00 | 3.97% | 2.82M | +184,698 | +7.01% | 2025-09-30 |
| Affinity Asset Advisors, Llc | $4,664.00 | 3.73% | 2.65M | +2M | +296.99% | 2025-09-30 |
| Acadian Asset Management Llc | $4,024.00 | 3.22% | 2.29M | +178,169 | +8.45% | 2025-09-30 |
| Renaissance Technologies Llc | $3,552.00 | 2.84% | 2.02M | -77,285 | -3.69% | 2025-09-30 |
| Sio Capital Management, Llc | $2,512.00 | 2.01% | 1.43M | -804,505 | -36.04% | 2025-09-30 |
| Driehaus Capital Management Llc | $2,464.00 | 1.97% | 1.4M | 0 | 0% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $2,376.00 | 1.9% | 1.35M | +200,000 | +17.39% | 2025-09-30 |
| Kennedy Capital Management Llc | $1,948.00 | 1.56% | 1.11M | -395,691 | -26.34% | 2025-09-30 |
| Ikarian Capital, Llc | $1,928.00 | 1.54% | 1.1M | +1M | New | 2025-09-30 |
| Millennium Management Llc | $1,736.00 | 1.39% | 986,293 | -66,041 | -6.28% | 2025-09-30 |